Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III disappointment for GSK/Tolerx-partnered drug follows last fall's Phase III miss by Lilly and MacroGenics' anti-CD3 antibody in same indication.
Advertisement

Related Content

GSK Highlights R&D Productivity Gains In First Quarter
GSK Highlights R&D Productivity Gains In First Quarter
GSK Announces Share Buyback Program As Pretax Profits Fall By 52% In 2010
GSK Signs Deal For Tolerx Anti-CD3 Antibody For Type 1 Diabetes
GSK Signs Deal For Tolerx Anti-CD3 Antibody For Type 1 Diabetes
Lilly Sweet On MacroGenics’ Novel Diabetes Drug Teplizumab

Topics

Advertisement
UsernamePublicRestriction

Register

PS071946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel